Ferric carboxymaltose · Injectafer / Ferinject

Other

Approvedregulatory verdict

Evidence outlook

Approved: Heart Failure, Chronic Kidney Disease, Iron Deficiency Anemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
CA
  • FERINJECT (ferric carboxymaltose) is indicated: • for the treatment of iron deficiency anemia (IDA) in adult and pediatric patients 1 year of age and older when oral iron preparations are not tolerated or are ineffective. • for the treatment of iron deficiency (ID) in adult patients with heart failure and New York Heart Association (NYHA) class II/III to improve exercise capacity. The diagnosis of iron deficiency must be based on laboratory tests.
Product first approved 2024Health Canada
Featured evidence outside this drug's tracked markets:NCT00396292 · Anemia · Phase 3 · completed · Partial signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (45)
Chronic Kidney Disease
NCT00994318 · Vifor Pharma
2009-12 – 2014-02 · Iron Deficiency Anaemia, Chronic Kidney Disease
What this study did
NCT00548691 · American Regent, Inc.
2007-10 – 2009-07 · Anemia
What this study did
NCT00317226 · American Regent, Inc.
2005-06 – 2007-09 · Anemia
What this study did
Heart Failure
NCT03833336 · Institut de Recerca Biomèdica de Lleida
2017-08-23 – 2024-12-20 · Heart Failure With Normal Ejection Fraction, Ferropenic Anemia
What this study did
NCT03991000 · Dr. med. Mahir Karakas
2019-02-28 – 2021-12-15 · Cardiovascular Diseases, Anemia, Iron-deficiency, Acute Myocardial Infarction, Atrial Fibrillation, Systolic Heart Failure
What this study did
NCT01394562 · Vifor Pharma
2011-07 – 2016-05 · Iron Deficiency, Chronic Heart Failure
What this study did
Iron Deficiency Anemia
NCT05590260 · NICHD Global Network for Women's and Children's Health
2023-05-30 – 2025-07-28 · Postpartum Anemia
What this study did
NCT04976179 · University of Lagos, Nigeria
2021-08-09 – 2023-06-15 · Iron Deficiency Anemia of Pregnancy
What this study did
NCT03523117 · American Regent, Inc.
2019-01-31 – 2021-01-29 · Iron Deficiency Anemia
What this study did
NCT03591406 · Vifor (International) Inc.
2017-07-03 – 2019-02-25 · Iron Deficiency Anemia
What this study did
NCT02541708 · Ifakara Health Institute
2015-09 – 2018-04 · Iron-Deficiency Anemia
What this study did
NCT01837082 · University of Ulm
2013-04 – 2015-12 · Heart Failure, Iron Deficiency, Anemia
What this study did
NCT01101399 · Vifor Pharma
2010-05 – 2013-11 · Iron-Deficiency Anemia
What this study did
NCT00703937 · American Regent, Inc.
2008-07 – 2011-03 · Anemia
What this study did
NCT00704028 · American Regent, Inc.
2008-06 – 2011-03 · Anemia
What this study did
NCT00704353 · American Regent, Inc.
2008-06 – 2011-03 · Anemia
What this study did
NCT00821717 · Vifor Pharma
2008-12 – 2011-01 · Chronic Heart Failure, Iron Deficiency, Iron Deficiency Anemia, Anaemia
What this study did
NCT00810030 · Vifor Pharma
2008-10 – 2010-04 · Inflammatory Bowel Disease, Anemia, Iron Deficiency, Iron-Deficiency Anemia, Crohn's Disease, Ulcerative Colitis
What this study did
NCT00520780 · Vifor Pharma
2007-04 – 2009-09 · Chronic Heart Failure, Iron Deficiency, Iron Deficiency Anemia, Anaemia
What this study did
NCT00548860 · American Regent, Inc.
2007-10 – 2009-07 · Anemia
What this study did
NCT00740246 · American Regent, Inc.
2005-07 – 2006-05 · Anemia
What this study did
Other / comorbidity
NCT05744219 · Jon Unosson
2024-09-04 – 2028-03-30 · Surgery, Liver Metastases, Liver Cancer, Pancreas Cancer, Aortic Aneurysm
What this study did
NCT04625530 · University Hospital, Basel, Switzerland
2021-08-01 – 2026-12-31 · Gynaecological Carcinoma
What this study did
NCT05226169 · Asan Medical Center
2022-04-29 – 2026-11-30 · Advanced Gastric Carcinoma
What this study did
NCT03769441 · University Medical Center Groningen
2019-08-02 – 2024-08-19 · Iron-deficiency, Transplant-Related Disorder
What this study did
NCT04187716 · Samsung Medical Center
2020-02-01 – 2020-12-01 · Cancer Anaemia
What this study did
NCT01692418 · University College, London
2014-01 – 2019-05 · Anaemia
What this study did
NCT01513369 · GWT-TUD GmbH
2012-08 – 2019-04 · Type 2 Diabetes Mellitus, Iron Deficiency
What this study did
NCT02453334 · American Regent, Inc.
2015-05-23 – 2018-01-04 · Cancer and Chemotherapy Related Anemia
What this study did
NCT02397057 · American Regent, Inc.
2015-01 – 2018-01 · Restless Legs Syndrome (RLS)
What this study did
NCT01690585 · University Hospital, Rouen
2013-01 – 2017-07 · Gastrointestinal Hemorrhage, Anemia
What this study did
NCT02125344 · GBG Forschungs GmbH
2014-12 – 2017-01-30 · Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, HER2 Positive Breast Cancer, Inflammatory Breast Cancer
What this study did
NCT01787526 · Medical University of Graz
2014-06 – 2016-08 · Iron Deficiency
What this study did
NCT01725789 · National Cancer Center, Korea
2012-11 – 2016-04 · Anemia
What this study did
NCT01154491 · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2010-06 – 2013-05 · Hip Fractures
What this study did
NCT00810004 · Vifor Pharma
2009-02 – 2010-10 · Iron Deficiency, Inflammatory Bowel Disease
What this study did
NCT00354484 · American Regent, Inc.
2006-05 – 2007-01 · Postpartum Anemia
What this study did
NCT00395993 · American Regent, Inc.
2005-05 – 2006-06 · Anemia
What this study did
NCT00396292 · American Regent, Inc.
2005-02 – 2006-02 · Anemia
What this study did
Phase 2/3 (3)
Iron Deficiency Anemia
NCT07648628 · ESI-PGIMSR, Basaidarapur
2024-03-01 – 2025-08-16 · Anemia, Anemia, Postpartum, Iron Deficiency Anemia of Pregnancy, Iron Deficiency Anemia Treatment, FCM
What this study did
Other / comorbidity
NCT07217873 · Columbia University
2025-11-21 – 2027-10-31 · Scoliosis Correction, Iron Deficiency, Transfusion Blood, Surgery Complications, Spinal Fusion, Scoliosis Idiopathic Adolescent, Scoliosis Neuromuscular
What this study did
NCT00929409 · Norwegian University of Science and Technology
2009-06 – 2010-07 · Anemia, Iron-Deficiency, Puerperal Disorders, Depression, Postpartum
What this study did
Phase 2 (19)
Heart Failure
NCT03218384 · NYU Langone Health
2017-09-07 – 2022-04-04 · Iron-deficiency
What this study did
NCT03079518 · RWTH Aachen University
2017-03-10 – 2017-10-25 · Heart Failure, Systolic, Iron Deficiency
What this study did
Iron Deficiency Anemia
NCT04968379 · American Regent, Inc.
2022-07-21 – 2024-12-12 · Iron Deficiency, Anaemia
What this study did
NCT02826681 · American Regent, Inc.
2017-07-10 – 2022-07-01 · Restless Legs Syndrome (RLS)
What this study did
NCT02469480 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2015-03 – 2020-08 · Metastatic Colorectal Cancer
What this study did
NCT02949947 · M.D. Anderson Cancer Center
2017-12-18 – 2019-03-06 · Malignant Neoplasms of Mesothelial and Soft Tissue, Gastrointestinal Stromal Tumor With Neurogenic Differentiation
What this study did
NCT02410213 · American Regent, Inc.
2015-02-19 – 2017-06-01 · Iron Deficiency Anemia (IDA)
What this study did
NCT01307007 · American Regent, Inc.
2010-09 – 2013-08 · Iron Deficiency Anemia
What this study did
NCT01290315 · American Regent, Inc.
2009-08 – 2013-08 · Iron Deficiency Anemia
What this study did
NCT00882414 · Vifor Pharma
2006-12 – 2010-01 · Thrombocytosis, Iron-Deficiency Anemia
What this study did
Other / comorbidity
NCT07822607 · University Hospital, Montpellier
2026-10 – 2030-10 · Restless Legs Syndrome (RLS)
What this study did
NCT02628860 · National Cancer Center, Korea
2014-01 – 2020-04-27 · Pancreatic Cancer, Anemia
What this study did
NCT03050424 · Royal Brompton & Harefield NHS Foundation Trust
2017-04-01 – 2019-01-01 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01447628 · Imperial College London
2011-03-29 – 2017-12-22 · Pulmonary Arterial Hypertension, Iron Deficiency
What this study did
NCT02599012 · Samsung Medical Center
2015-09-12 – 2017-12 · Cancer, Anemia
What this study did
NCT02517151 · Istituto Clinico Humanitas
2014-10 – 2016-12 · Chronic Fatigue, Inflammatory Bowel Disease
What this study did
NCT02409459 · American Regent, Inc.
2015-03 – 2016-03 · Iron Deficiency, Fibromyalgia
What this study did
NCT00685815 · American Regent, Inc.
2006-11 – 2012-12 · Restless Legs
What this study did
NCT01382901 · American Regent, Inc.
2006-03 – 2007-07 · Restless Legs Syndrome (RLS)
What this study did
Phase 1 (6)
Heart Failure
NCT02737995 · NYU Langone Health
2015-05 – 2016-01 · Chronic Heart Failure
What this study did
Iron Deficiency Anemia
NCT03399084 · Sandoz
2017-11-29 – 2019-01-15 · Iron Deficiency Anemia
What this study did
Other / comorbidity
NCT07606105 · Sichuan Huiyu Pharmaceutical Co., Ltd
2026-05-19 – 2027-01-26 · Healthy Adult
What this study did
NCT06895993 · Sichuan Huiyu Pharmaceutical Co., Ltd
2025-04-07 – 2025-05-08 · Healthy Adult
What this study did
NCT06080555 · Sichuan Huiyu Pharmaceutical Co., Ltd
2023-10-09 – 2024-03-22 · Iron Deficiency, Anaemia
What this study did
NCT02009943 · Denver Health and Hospital Authority
2017-02 – 2017-09 · ICU Anemia, Functional Iron Deficiency
What this study did
Phase 4 (66)
Chronic Kidney Disease
NCT07414199 · Children's Hospital of Orange County
2026-01-31 – 2026-12-31 · Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease, Iron Deficiency Anaemia Due to Dietary Causes, Iron Deficiency Anemia Treatment, Iron Deficiency Anemia Secondary to IBD or Gastric Bypass, Iron Deficiency Anemias
What this study did
NCT03388385 · Carol Davila University of Medicine and Pharmacy
2017-09-20 – 2022-12-20 · Renal Anemia, Iron Toxicity, Oxidative Stress, Endothelial Dysfunction
What this study did
NCT04862715 · King's College Hospital NHS Trust
2019-04-26 – 2022-02-21 · CKD Stage 3, CKD Stage 4, Iron-deficiency
What this study did
NCT02198495 · Medical University of Vienna
2014-09 – 2019-05 · Anemia of Chronic Kidney Disease
What this study did
NCT02232906 · Hospital Aleman
2011-03 – 2013-09 · Iron Deficiency, Anaemia
What this study did
Heart Failure
NCT05793996 · Tomsk National Research Medical Center of the Russian Academy of Sciences
2023-04-28 – 2026-12 · Chronic Heart Failure, Iron Deficiency, Latent
What this study did
NCT03074591 · Charite University, Berlin, Germany
2017-08-01 – 2024-04-10 · Iron-deficiency, Heart Failure
What this study did
NCT05477498 · Cantonal Hospital, Baselland
2021-12-01 – 2022-12-31 · Heart Failure With Normal Ejection Fraction, Iron-deficiency
What this study did
NCT03380520 · Hasselt University
2017-10-01 – 2021-08-04 · Heart Failure
What this study did
NCT03871699 · Hospital Moinhos de Vento
2019-08-30 – 2021-02-28 · Cardiac Failure, Systolic Heart Failure, Heart Failure, Systolic
What this study did
NCT02937454 · Vifor (International) Inc.
2017-04-03 – 2020-07-21 · Iron Deficiency, Heart Failure
What this study did
NCT01978028 · University of Zurich
2013-10 – 2017-12-31 · Heart Failure
What this study did
NCT01922479 · National University Hospital, Singapore
2013-09 – 2015-12 · Heart Failure, Anemia, Iron Deficiency
What this study did
NCT01453608 · Vifor Pharma
2011-10 – 2015-01 · Iron Deficiency, Chronic Heart Failure
What this study did
Iron Deficiency Anemia
NCT07772453 · Zhaojian Niu,MD
2026-08 – 2028-03 · Gastric Cancer (GC), Iron Deficiency Anemia (IDA), Post-Operative Anemia, Radical Gastrectomy
What this study did
NCT06061393 · Western Galilee Hospital-Nahariya
2023-11-02 – 2027-12 · Anemia, Iron Deficiency, Pregnancy Anemia
What this study did
NCT05708170 · Liverpool Hope University
2023-01 – 2027-01 · Iron Deficiency Anemia
What this study did
NCT04168346 · Helsinki University Central Hospital
2019-11 – 2026-11 · Gastric Cancer, Anemia, Surgery, Iron Deficiency Anemia, Surgery--Complications
What this study did
NCT07880314 · Pakistan Air Force (PAF) Hospital Islamabad
2026-04-20 – 2026-09-20 · Postpartum Fatigue, Iron Deficiency Anemia
What this study did
NCT07053475 · Syed Hamza Mufarrih
2025-04-02 – 2026-03-31 · Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Iron Deficiency, Iron-deficiency Anemia (IDA)
What this study did
NCT06911034 · CMH Multan Institute of Medical Sciences
2024-02-01 – 2024-09-30 · Iron Deficiency Anemia (IDA), Pregnancy
What this study did
NCT05358509 · Thomas Jefferson University
2021-03-15 – 2024-01-21 · Iron Deficiency Anemia, Infant, Low Birth Weight, Anemia of Pregnancy
What this study did
NCT05098249 · Donat R. Spahn
2021-11-11 – 2023-05-23 · Anemia, Iron-deficiency, Hypophosphatemia
What this study did
NCT04616092 · Seoul National University Hospital
2020-11 – 2023-04 · Cerebral Aneurysm Unruptured, Iron Deficiency Anemia, Surgery
What this study did
NCT04627181 · Christian Medical College, Vellore, India
2020-11-18 – 2021-03 · Iron Deficiency Anemia, B12 Deficiency Anemia
What this study did
NCT02086968 · American Regent, Inc.
2014-01-01 – 2017-10 · Iron Deficiency Anemia Secondary to IBD or Gastric Bypass
What this study did
NCT01950247 · American Regent, Inc.
2013-08-15 – 2015-06 · Iron Deficiency Anemia (IDA)
What this study did
NCT00706667 · University of Zurich
2008-05 – 2012-12 · Iron Deficiency Anemia
What this study did
NCT01245777 · University of Zurich
2009-10 – 2012-12 · Restless Leg Syndrome, Iron Deficiency Anemia
What this study did
NCT01100879 · Vifor Pharma
2010-03 – 2011-10 · Iron-Deficiency Anemia
What this study did
Other / comorbidity
NCT06833788 · Assistance Publique - Hôpitaux de Paris
2025-10-22 – 2028-10-30 · Postpartum Depression (PPD)
What this study did
NCT07359599 · Ziekenhuis Oost-Limburg
2026-01-27 – 2028-10 · Pulmonary Hypertension, Iron Deficiency
What this study did
NCT07370688 · Erasmus Medical Center
2024-08-12 – 2028-07 · Aortic Valve Stenosis, Iron Deficiency, TAVI(Transcatheter Aortic Valve Implantation), Cardiovascular Diseases
What this study did
NCT07476859 · Fundación para la Investigación del Hospital Clínico de Valencia
2026-03-05 – 2028-05 · Acute Coronary Syndromes (ACS), Iron Deficiencies, Elderly (People Aged 65 or More)
What this study did
NCT05759078 · Wroclaw Medical University
2022-09-22 – 2026-12-31 · Myocardial Infarction, Acute
What this study did
NCT04083755 · Biobizkaia Health Research Institute
2019-08-15 – 2025-12-31 · Anemia, Peripheral Arterial Occlusive Disease
What this study did
NCT06686693 · United States Army Research Institute of Environmental Medicine
2022-04-15 – 2025-09-30 · Hypoxia
What this study did
NCT04786769 · Hospital de Santa Cruz, Portugal
2022-01 – 2025-06 · Aortic Stenosis, Iron-deficiency
What this study did
NCT06080893 · Istanbul University
2023-10-10 – 2025-03-24 · Hip Fractures, Anemia, Complication,Postoperative
What this study did
NCT03680456 · Kepler University Hospital
2020-03-06 – 2025-01-31 · Blood Loss Anemia
What this study did
NCT05429749 · Seoul National University Bundang Hospital
2020-07-30 – 2024-12-31 · Hip Fractures
What this study did
NCT02632760 · Bayside Health
2016-07-15 – 2024-11-27 · Anaemia
What this study did
NCT05505006 · Azienda Ospedaliera Universitaria Integrata Verona
2021-03-02 – 2024-08-13 · Anemia, Tumor
What this study did
NCT03574311 · Turku University Hospital
2018-10-02 – 2023-12 · Coronary Artery Disease, Postoperative Complications, Aortic Valve Stenosis, Mitral Valve Disease, Aortic Aneurysm, Thoracic
What this study did
NCT05114278 · Assistance Publique - Hôpitaux de Paris
2022-07-08 – 2023-07-11 · Celiac Disease
What this study did
NCT04510870 · Dextra Fertility Clinic
2020-08-17 – 2022-02-28 · Iron Deficiency, Infertility
What this study did
NCT04035902 · Konkuk University Medical Center
2021-03 – 2021-12 · Osteoarthritis, Hip
What this study did
NCT03632525 · University of Oxford
2019-02-22 – 2021-10-26 · Cystic Fibrosis, Iron-deficiency
What this study did
NCT03759964 · St Joseph University, Beirut, Lebanon
2018-12-15 – 2021-01-02 · Anemia, Iron Deficiency
What this study did
Early phase / not applicable (20)
Chronic Kidney Disease
NCT06994065 · Sindh Institute of Urology and Transplantation
2025-04-01 – 2025-11-30 · Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease
What this study did
Iron Deficiency Anemia
NCT07721519 · Hawler Medical University
2026-09-01 – 2028-12-01 · Iron Deficiency Anemia in Pregnancy
What this study did
NCT04915820 · Jomo Kenyatta University of Agriculture and Technology
2021-05-29 – 2021-09-09 · Iron Deficiency Anemia, Vaccine Response Impaired, COVID-19 Vaccine, Iron Deficiency Anemia Treatment
What this study did
NCT04912661 · Swiss Federal Institute of Technology
2021-05-29 – 2021-09-09 · Iron Deficiency Anemia, Vaccine Preventable Disease, Vaccine Response Impaired, Iron Deficiency Anemia Treatment
What this study did
NCT03625661 · Institut Cancerologie de l'Ouest
2014-02-02 – 2017-06-12 · Iron Deficiency Anemia
What this study did
Other / comorbidity
NCT07057973 · Xuanwu Hospital, Beijing
2025-07-01 – 2026-07-01 · Ferric Carboxymaltose
What this study did
NCT04653181 · Helsinki University Central Hospital
2020-10-01 – 2025-12-31 · Colon Cancer
What this study did
NCT05669872 · Asan Medical Center
2023-02 – 2025-12 · Gynecologic Cancer
What this study did
NCT06437080 · Akram Medical Complex
2022-10-10 – 2025-10-16 · Hypoferritenemia Without Anemia (HWA), Iron Deficiency Without Anemia)
What this study did
NCT05309499 · Kazan State Medical University
2021-12-05 – 2025-09-15 · Myocardial Infarction, Iron-deficiency
What this study did
NCT07340450 · Shahida Islam Medical Complex
2025-02-18 – 2025-08-18 · Postpartum Anaemia
What this study did
NCT07115121 · Muhammad Aamir Latif
2025-02-02 – 2025-07-31 · Anemia
What this study did
NCT04141631 · University Hospital, Montpellier
2020-01-13 – 2022-06-15 · Cardiac Surgery, Transfusion, Perioperative Anemia
What this study did
NCT02979132 · Prof. Michael B. Zimmermann
2017-09-01 – 2019-03-31 · Iron Absorption
What this study did
NCT02800746 · Konkuk University Medical Center
2018-06 – 2018-12 · Prognathic Surgery
What this study did
NCT04246021 · King Hussein Cancer Center
2016-06-15 – 2017-12-31 · Anemia, Cancer
What this study did
NCT03707249 · Royal Centre for Defence Medicine
2016-01-19 – 2017-12-07 · Iron-deficiency, Ventricular Function, Pulmonary Vascular Resistance Abnormality, Altitude Hypoxia
What this study did
NCT02496377 · University Hospital, Montpellier
2014-08-29 – 2016-10-16 · Allogenic Transfusion, Perioperative Anaemia, Knee Arthroplasty, Hip Arthroplasty
What this study did
NCT02308449 · University of Oxford
2014-10 – 2016-01 · Iron Deficiency
What this study did
NCT01847352 · University of Oxford
2013-02 – 2014-04 · Lung Hypoxia, Pulmonary Arterial Hypertension, Iron Deficiency
What this study did
Used as active comparator (11)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (8)
Iron Deficiency Anemia
NCT07687784 · AFT Pharmaceuticals, Ltd.
2026-12 – 2028-07 · Iron Deficiency Anemia (IDA)
What this study did
NCT03817957 · Prof. Dr. Frank Behrens
2018-09-18 – 2024-10-21 · Iron Deficiency Anemia
What this study did
NCT04587141 · Fondazione IRCCS Policlinico San Matteo di Pavia
2020-01-01 – 2023-06-30 · Iron Deficiency Anemia, Inflammatory Bowel Diseases
What this study did
NCT04087993 · Dr. Frank Behrens
2020-05-15 – 2020-12-31 · Iron Deficiency Anemia
What this study did
NCT03238911 · Pharmacosmos A/S
2017-10-24 – 2018-06-19 · Iron Deficiency Anaemia, Iron Deficiency Anemia
What this study did
NCT03237065 · Pharmacosmos A/S
2017-10-30 – 2018-05-29 · Iron Deficiency Anaemia, Iron Deficiency Anemia
What this study did
NCT02694978 · AMAG Pharmaceuticals, Inc.
2016-02-29 – 2017-07-17 · Iron Deficiency Anemia
What this study did
Other / comorbidity
NCT02680756 · Shield Therapeutics
2016-01 – 2019-01 · Anemia, Iron-Deficiency, Inflammatory Bowel Disease, Crohn's Disease
What this study did
Phase 4 (3)
Heart Failure
NCT05702970 · University of Padova
2024-01-15 – 2025-10-31 · Heart Failure, Iron-deficiency, Heart Failure, Systolic, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Vitamin D Deficiency
What this study did
Other / comorbidity
NCT02905539 · Universität des Saarlandes
2016-07 – 2020-06 · Anemia, Iron-Deficiency
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Early phase / not applicable (1)
Iron Deficiency Anemia
NCT04343170 · Tanta University
2023-09-01 – 2024-10-01 · Ultra-short-term, Iron Deficiency Anemia, Scoliosis Idiopathic
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Heart Failure: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ferric Carboxymaltose (Injectafer / Ferinject): this drugApprovedIron Complex (iv)Iron repletionPartial signal
NCT03037931: Primary endpoint, hierarchical composite of death and heart failure hospitalization at 12 months and change in 6-minute walk distance at 6 months (significance level 0.01): unmatched win ratio 1.10 (99% CI 0.99 to 1.23), Wilcoxon-Mann-Whitney P=0.02. Components, ferric carboxymaltose vs placebo: deaths 131 (8.6%) vs 158 (10.3%); heart failure hospitalizations 297 vs 332; 6-minute walk change +8 vs +4 m. missed
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Reliable signal
NCT04564742: Primary hierarchical composite outcome (win ratio analysis, DAPA-MI): win ratio 1.34 (95% CI 1.20-1.50), P<0.001, favoring dapagliflozin over placebo; n=4017 (2019 dapagliflozin vs 1998 placebo)
NCT03619213: Primary composite outcome (worsening heart failure or cardiovascular death): dapagliflozin 16.4% vs placebo 19.5%; hazard ratio 0.82 (95% CI 0.73-0.92, p<0.001)
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT03057951: Primary composite endpoint (CV death or HF hospitalization) event rate: 13.8% (empagliflozin) vs 17.1% (placebo); HR 0.79, 95% CI 0.69-0.90; 21% relative risk reduction.
NCT03057977: Primary composite outcome (cardiovascular death or hospitalization for worsening heart failure) at median 16 months: 19.4% (361/1863) with empagliflozin vs 24.7% (462/1867) with placebo; hazard ratio 0.75 (95% CI 0.65-0.86), P<0.001
Finerenone (Kerendia)ApprovedSmall moleculeMineralocorticoid receptorReliable signal
NCT04435626: Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events (From randomization up until the end of study, with an average study duration of 32 months): Finerenone (BAY94-8862) 1083 events | Placebo 1283 events
Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX)ApprovedSmall moleculeNKCC2Weak signalFeatured results are non-efficacy only in this race
Furosemide (subcutaneous, SQ Innovation) (Lasix ONYU)ApprovedSmall moleculeNKCC2not yet gradedNo reviewed efficacy summary in this indication
Isosorbide Dinitrate / Hydralazine (BiDil)ApprovedSmall moleculeHydralazine/isosorbide dinitrate (fixed combination)Partial signal
NCT00047775: Primary composite score (all-cause mortality, first heart-failure hospitalization, quality of life) favoured isosorbide dinitrate/hydralazine vs placebo (p=0.021); the trial stopped early for a 43% reduction in all-cause mortality (p=0.012) (BiDil label, A-HeFT).
Ivabradine (Corlanor)
ApprovedUS marketing discontinued
Small moleculeIf (funny) channelReliable signal
NCT02441218: Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure. (All over the study (up to 42 months).): Ivabradine 793 participants | Placebo 937 participants
Sacubitril / Valsartan (Entresto)ApprovedSmall moleculeNeprilysin + Angiotensin II receptor (dual)Partial signal
NCT01035255: Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization (up to 51 months): LCZ696 — Primary Composite: 914 participants; CV death: 558 participants; 1st HF Hospitalization: 537 participants | Enalapril — Primary Composite: 1117 participants; CV death: 693 participants; 1st HF Hospitalization: 658 participants
NCT01920711: Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations. (Total follow up time (up to 57 months)): LCZ696 — Primary Composite Events: 894 Events; Total Hospitalizations for heart failure: 690 Events; Cardiovascular death: 204 Events | Valsartan — Primary Composite Events: 1009 Events; Total Hospitalizations for heart failure: 797 Events; Cardiovascular death: 212 Events missed
Sotagliflozin (Inpefa)ApprovedSmall moleculeSGLT1/2 (dual)Partial signal
NCT03315143: Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF) (Up to 30 months): Sotagliflozin 5.6 events per 100-person years | Placebo 7.5 events per 100-person years
NCT03521934: Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF) (Up to 21.9 months): Sotagliflozin 51 events per 100-person years | Placebo 76.3 events per 100-person years
Torsemide (Soaanz)ApprovedSmall moleculeNKCC2not yet gradedNo reviewed efficacy summary in this indication
Vericiguat (Verquvo)ApprovedSmall moleculeSoluble guanylate cyclasePartial signal
NCT02861534: CV death or first HF hospitalization, vericiguat vs placebo: 897 of 2526 (35.5%) vs 972 of 2524 (38.5%) over a median 10.8 months; HR 0.90 (95% CI 0.82 to 0.98), P = 0.02. Met.
NCT05093933: Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization: Participants With an Event Per 100 Patient-Years (Up to approximately 36 months (from randomization to the primary completion data cutoff)): Vericiguat 11.3 Pts. with event/100 patient-yrs at risk | Placebo 12.2 Pts. with event/100 patient-yrs at risk missed
AlprostadilPhase 3Small moleculeProstaglandin E1 receptornot yet gradedNo reviewed efficacy summary in this indication
BalcinrenonePhase 3Small moleculeMineralocorticoid receptorPartial signalNo reviewed efficacy summary in this indication
Baxdrostat (Baxfendy)Phase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
CardiAMPPhase 3Cell therapyCardiac cell therapyPartial signal
NCT02438306: 3-tiered Finkelstein-Schoenfeld primary endpoint at 12 months (interim, 102 of eventual 125 patients): Tier 1 all-cause death 5.6% CardiAMP vs 5.3% control (P=.42); Tier 2 MACCE 16.7% vs 15.8% (P=.82); Tier 3 6MWT change +36.1m vs +33.4m (P=.6) - none reached significance; DSMB futility review concluded the trial was unlikely to meet its primary endpoint missed
CoramitugPhase 3Monoclonal antibodyTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
ElecoglipronPhase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Ferric Derisomaltose (Monoferric / Monofer)Phase 3Iron Complex (iv)Iron repletionWeak signal
NCT00537186: Single-arm, open-label safety study with no comparator and no formal efficacy test. All registered primary outcomes are safety measures (adverse events, serious adverse events, physical examination, vital signs, laboratory tests). A published pilot study that appears to be this trial (Hildebrandt et al. 2010, n=20) reported no treatment-related adverse reactions and no clinically significant changes in laboratory safety tests or vital signs over 8 weeks.
HiCM-188 (allogeneic iPSC-Cardiomyocytes)Phase 3Cell therapyCardiac cell therapyPartial signalNo reviewed efficacy summary in this indication
Icodextrin (peritoneal Ultrafiltration) (Extraneal)Phase 3Glucose Polymer Solution (peritoneal Dialysis)Peritoneal ultrafiltrationWeak signal
NCT00368641: All-cause Hospitalization (Unadjusted) (6 to 24 months): Intervention Group 5.33 hospitalizations per year (95% CI 3.13 to 9.05) vs Standard Therapy 1.69 hospitalizations per year (95% CI 0.95 to 2.99)
Levosimendan (Simdax)Phase 3Small moleculeCardiac troponin C (calcium sensitizer)Partial signal
NCT00348504: All-cause mortality at 180 days occurred in 173 (26%) patients in the levosimendan group and 185 (28%) patients in the dobutamine group (hazard ratio, 0.91; 95% confidence interval, 0.74-1.13; P = .40). missed
NCT00048425: REVIVE II, n=600: 5-day clinical-course composite primary endpoint improved 33% more often and worsened 26% less often with levosimendan vs placebo (p=0.015).
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistnot yet gradedNo reviewed efficacy summary in this indication
Omecamtiv MecarbilPhase 3Small moleculeCardiac myosin (activator)Reliable signal
NCT02929329: Time to Cardiovascular Death or First Heart Failure Event (From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.): Omecamtiv Mecarbil 37% vs Placebo 39.1%
NCT03759392: Change in Peak Oxygen Uptake on Cardiopulmonary Exercise Testing From Baseline to Week 20 (Baseline and Week 20): Omecamtiv Mecarbil -0.239 mL/min/kg (Standard Error 0.1718) vs Placebo 0.207 mL/min/kg (Standard Error 0.2412) missed
OPC-61815 (Samtasu)Phase 3Small moleculeVasopressin V2 receptorPartial signal
NCT03772041: Change From Baseline in Body Weight (Baseline, Day 6): OPC-61815 Injection 16 mg -1.67 kg (95% CI -1.93 to -1.41) vs Tolvaptan Tablet 15mg -1.36 kg (95% CI -1.62 to -1.1)
QiShenYiQiPhase 3BotanicalTraditional Chinese medicine (multi-component)Partial signalNo reviewed efficacy summary in this indication
Recombinant Human Neuregulin-1 (rhNRG-1) (Neucardin)Phase 3Protein / enzyme therapeuticErbB2/ErbB4 (neuregulin pathway)Partial signalNo reviewed efficacy summary in this indication
Rexlemestrocel-LPhase 3Cell therapyMesenchymal precursor cells (MPCs)Weak signalFeatured results are safety only in this race
Sotatercept (Winrevair)Phase 3Protein / enzyme therapeuticActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
Tolvaptan (Samsca)Phase 3Small moleculeVasopressin V2 receptorPartial signal
NCT00071331: All-cause mortality: tolvaptan 25.9% vs placebo 26.3% (HR 0.98, 95% CI 0.87-1.11, P=.68). Composite of CV death or HF hospitalization: tolvaptan 42.0% vs placebo 40.2% (HR 1.04, 95% CI 0.95-1.14, P=.55). missed
VicadrostatPhase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
DanicamtivPhase 2/3Small moleculeCardiac myosin (activator)Weak signal
NCT03447990: Troponin I increase: 3/12 danicamtiv vs 0/12 placebo in SAD cohorts; 7/30 danicamtiv vs 0/10 placebo in MAD cohorts.
IstaroximePhase 2/3Small moleculeNa-K ATPase / SERCA2aPartial signal
NCT02617446: Change in E/Ea Ratio (24 hours): Istaroxime 0.5 µg/kg/Min -4.55 Unitless ratio (95% CI -6.05--3.04) vs Placebo Cohort I -1.55 Unitless ratio (95% CI -3.77-0.67) vs Istaroxime 1.0 µg/kg/Min -3.16 Unitless ratio (95% CI -4.09--2.24) vs Placebo Cohort II -1.08 Unitless ratio (95% CI -2.30-0.13); p=0.029 (Istaroxime 0.5 µg/kg/Min vs Placebo Cohort I), p=0.009 (Istaroxime 1.0 µg/kg/Min vs Placebo Cohort II)
AC01Phase 2Small moleculeGhrelin receptorWeak signalNo reviewed efficacy summary in this indication
ADR-002KPhase 2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
Bucindolol (Gencaro)Phase 2Small moleculeBeta-1/beta-2 adrenergic receptor (genotype-guided)Partial signal
NCT01970501: Time to First Event of Symptomatic Atrial Fibrillation/Atrial Flutter (AF/AFL) or All Cause Mortality (ACM) During the 24-week Follow-up Period After Establishment of Stable Sinus Rhythm (SR) on Study Drug [End of Treatment Week 24]. (end of treatment week 24): Bucindolol Hydrochloride 35.9 days (IQR 9 to 53) vs Metoprolol Succinate 33.2 days (IQR 6 to 47) missed
CDR132LPhase 2RNA / oligonucleotidemicroRNA-132Weak signalFeatured results are safety only in this race
Corteria COR-1167Phase 2PeptideCorticotropin-releasing factor receptor 2not yet gradedNo reviewed efficacy summary in this indication
DelocamtenPhase 2Small moleculeCardiac myosin (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
DeramiocelPhase 2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
HRS-9057Phase 2Small moleculeVasopressin V1a/V2 receptor (dual)Weak signalNo reviewed efficacy summary in this indication
HU6Phase 2Small moleculeMitochondrial uncouplingPartial signal
NCT05284617: Weight change at 3 months (450 mg HU6 dose): -6.8 lb from baseline (p<0.0001); -6.3 lb vs placebo (p=0.003)
Jia Shen TabletPhase 2BotanicalMulti-target (ginsenoside)Weak signalNo reviewed efficacy summary in this indication
JK07Phase 2Biologic (subtype unspecified)HER3 × ErbB4Weak signalFeatured results are safety only in this race
JTT-861Phase 2Small moleculePyruvate dehydrogenasePartial signalNo reviewed efficacy summary in this indication
Mavacamten (Camzyos)Phase 2Small moleculeCardiac myosin (inhibitor)Weak signalFeatured results are safety only in this race
Ninerafaxstat (IMB-101)Phase 2Small moleculeCardiac fatty-acid oxidationWeak signal
NCT04826159: Primary, resting cardiac PCr/ATP change from baseline (single arm, no comparator): Part 1 (type 2 diabetes and obesity) +0.39 (95% CI 0.16 to 0.62; P=0.002); Part 2 (with HFpEF) +0.15 (95% CI 0.03 to 0.26; P=0.02). Dobutamine-stress PCr/ATP (Part 1) is not reported in the abstract.
PexerelgonPhase 2Small moleculeRelaxin receptor (RXFP1) / relaxinPartial signalNo reviewed efficacy summary in this indication
PF-07328948Phase 2Small moleculeBranched-chain ketoacid dehydrogenase kinase (BDK)not yet gradedNo reviewed efficacy summary in this indication
R2R01Phase 2PeptideRelaxin receptor (RXFP1) / relaxinWeak signalNo reviewed efficacy summary in this indication
RibupatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Safiglipron (HRS-7535)Phase 2Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
TovinontrinePhase 2Small moleculePDE9Partial signalNo reviewed efficacy summary in this indication
Umiposgene Parvec (AB-1002)Phase 2Gene therapy / editingProtein inhibitor-1 (gene therapy)Weak signal
NCT04179643: Phase 1 first-in-human trial of a single antegrade coronary infusion of AB-1002 in NYHA III non-ischemic heart failure: no adverse events or serious adverse events were attributed by the investigators to the study treatment. Mean left ventricular ejection fraction rose from 30.5% at baseline to 42.2% at 12 months in cohort 1 and from 24.5% to 36.7% in cohort 2, and all patients with baseline and 12-month assessments had an improvement in ejection fraction of at least 5%.
XTR003Phase 2Diagnostic (pet Tracer)Myocardial fatty-acid metabolism (PET imaging)not yet gradedNo reviewed efficacy summary in this indication
AAV1.SERCA2aPhase 1/2Gene therapy / editingSERCA2a (gene therapy)not yet gradedNo reviewed efficacy summary in this indication
HS-001Phase 1/2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
HS235Phase 1/2PeptideActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
HucMSC Intramyocardial TherapyPhase 1/2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
PolyCorePhase 1/2SolutionPeritoneal ultrafiltrationnot yet gradedNo reviewed efficacy summary in this indication
Anhui HygeianCells EE001Phase 1Biologic (subtype unspecified)Cardiac cell therapyWeak signalNo reviewed efficacy summary in this indication
HJB647Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 61 furthest-along competitors are listed; 13 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(13 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Injectafer / Ferinject (Ferric carboxymaltose) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
November 2026 (1)
Phase 3Advanced Gastric CarcinomaRecruiting
Est. primary completion 2026-11-30 · NCT05226169 · CT.gov ↗
What to watch
December 2026 (2)
Phase 4Heart FailureRecruiting
Est. primary completion 2026-12 · NCT05793996 · CT.gov ↗
What to watch
Phase 4Myocardial Infarction, AcuteRecruiting
Est. primary completion 2026-12-31 · NCT05759078 · CT.gov ↗
What to watch
2027 (4)
August 2027 (1)
Phase 2/3Scoliosis Correction, Iron Deficiency, Transfusion Blood, Surgery Complications, Spinal Fusion, Scoliosis Idiopathic Adolescent …Recruiting
Est. primary completion 2027-08-31 · NCT07217873 · CT.gov ↗
What to watch
September 2027 (1)
Phase 4Iron Deficiency AnemiaRecruiting
Est. primary completion 2027-09 · NCT06061393 · CT.gov ↗
What to watch
November 2027 (1)
Phase 4Iron Deficiency AnemiaNot yet recruiting
Est. primary completion 2027-11 · NCT07772453 · CT.gov ↗
What to watch
December 2027 (1)
Phase 3Surgery, Liver Metastases, Liver Cancer, Pancreas Cancer, Aortic AneurysmRecruiting
Est. primary completion 2027-12-31 · NCT05744219 · CT.gov ↗
What to watch
2028 (5)
March 2028 (1)
Early phase / not applicableIron Deficiency AnemiaNot yet recruiting
Est. primary completion 2028-03-01 · NCT07721519 · CT.gov ↗
What to watch
April 2028 (1)
Phase 4Acute Coronary Syndromes (ACS), Iron Deficiencies, Elderly (People Aged 65 or More)Recruiting
Est. primary completion 2028-04 · NCT07476859 · CT.gov ↗
What to watch
June 2028 (1)
Phase 4Postpartum Depression (PPD)Recruiting
Est. primary completion 2028-06-22 · NCT06833788 · CT.gov ↗
What to watch
July 2028 (2)
Phase 4Aortic Valve Stenosis, Iron Deficiency, TAVI(Transcatheter Aortic Valve Implantation), Cardiovascular DiseasesRecruiting
Est. primary completion 2028-07 · NCT07370688 · CT.gov ↗
What to watch
Phase 4Pulmonary Hypertension, Iron DeficiencyRecruiting
Est. primary completion 2028-07 · NCT07359599 · CT.gov ↗
What to watch
2029 (1)
April 2029 (1)
Phase 2Restless Legs Syndrome (RLS)Not yet recruiting
Est. primary completion 2029-04 · NCT07822607 · CT.gov ↗
What to watch

See the full readout calendar ↗